Total operating revenue increased over 11% aided primarily by nearly 15% growth in clinical revenues (including joint agreements) against total expense growth of 6%.
Because of the very long time needed for discovery, development, and approval of pharmaceuticals, these costs can accumulate to nearly half the total expense.